<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04389827</url>
  </required_header>
  <id_info>
    <org_study_id>GKPTN2019</org_study_id>
    <nct_id>NCT04389827</nct_id>
  </id_info>
  <brief_title>Global Kidney Patient Trials Network</brief_title>
  <official_title>Global Kidney Patient Trials Network</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The George Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>George Clinical Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The George Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective international multi-centre, observational cohort study of incident and
      prevalent patients diagnosed with a kidney disease
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 5, 2020</start_date>
  <completion_date type="Anticipated">April 1, 2030</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2025</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>eGFR (estimated Glomerular Filtration Rate)</measure>
    <time_frame>Collected Six-Monthly (minimum)</time_frame>
    <description>Routine results</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Albuminuria</measure>
    <time_frame>Collected Six-Monthly (minimum)</time_frame>
    <description>Routine results</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Kidney Diseases</condition>
  <arm_group>
    <arm_group_label>Incident &amp; Prevalent Patients</arm_group_label>
    <description>Incident and prevalent patients diagnosed with a kidney disease at participating centres</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood and urine samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants will be recruited from units that provide a comprehensive nephrology service
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Documented diagnosis of primary kidney disease (refer to Appendix 9.1)

          2. Regular visits (at least 6 monthly) with a physician at a participating site

          3. eGFR &gt; 15 ml/min/1.73m2

          4. â‰¥ 2 years of age

          5. Willing and able to sign informed consent

          6. Willing to be approached about participation in interventional research studies

        Exclusion Criteria:

        1. Life-expectancy of less than 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Meg Jardine</last_name>
    <role>Principal Investigator</role>
    <affiliation>The George Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hiddo Lambers Heerspink</last_name>
    <role>Principal Investigator</role>
    <affiliation>The George Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lyndal Hones</last_name>
    <phone>+61 2 8052 4300</phone>
    <email>kidneynetwork@georgeinstitute.org.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Melinda Ho</last_name>
    <phone>+61 2 8052 4300</phone>
    <email>kidneynetwork@georgeinstitute.org.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The George Institute</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2042</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melinda Ho</last_name>
      <phone>+61 2 8052 4300</phone>
      <email>kidneynetwork@georgeinstitute.org.au</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <link>
    <url>http://www.diabetesatlas.org</url>
    <description>International Diabetes Federation. IDF Diabetes Atlas 8th edn. Brussels, Belgium:: International Diabetes Federation; 2017</description>
  </link>
  <reference>
    <citation>Luyckx VA, Tonelli M, Stanifer JW. The global burden of kidney disease and the sustainable development goals. Bull World Health Organ. 2018 Jun 1;96(6):414-422D. doi: 10.2471/BLT.17.206441. Epub 2018 Apr 20.</citation>
    <PMID>29904224</PMID>
  </reference>
  <reference>
    <citation>Tonelli M, Muntner P, Lloyd A, Manns BJ, Klarenbach S, Pannu N, James MT, Hemmelgarn BR; Alberta Kidney Disease Network. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet. 2012 Sep 1;380(9844):807-14. doi: 10.1016/S0140-6736(12)60572-8. Epub 2012 Jun 19.</citation>
    <PMID>22717317</PMID>
  </reference>
  <reference>
    <citation>Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004 Sep 23;351(13):1296-305. Erratum in: N Engl J Med. 2008;18(4):4.</citation>
    <PMID>15385656</PMID>
  </reference>
  <reference>
    <citation>McGrogan A, Franssen CF, de Vries CS. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrol Dial Transplant. 2011 Feb;26(2):414-30. doi: 10.1093/ndt/gfq665. Epub 2010 Nov 10. Review.</citation>
    <PMID>21068142</PMID>
  </reference>
  <reference>
    <citation>Strippoli GF, Craig JC, Schena FP. The number, quality, and coverage of randomized controlled trials in nephrology. J Am Soc Nephrol. 2004 Feb;15(2):411-9. Review.</citation>
    <PMID>14747388</PMID>
  </reference>
  <reference>
    <citation>Perkovic V, Craig JC, Chailimpamontree W, Fox CS, Garcia-Garcia G, Benghanem Gharbi M, Jardine MJ, Okpechi IG, Pannu N, Stengel B, Tuttle KR, Uhlig K, Levey AS. Action plan for optimizing the design of clinical trials in chronic kidney disease. Kidney Int Suppl (2011). 2017 Oct;7(2):138-144. doi: 10.1016/j.kisu.2017.07.009. Epub 2017 Sep 20. Review.</citation>
    <PMID>30675428</PMID>
  </reference>
  <reference>
    <citation>de Zeeuw D, Heerspink HJL, Jardine M, Perkovic V. Renal trials in diabetes need a platform: time for a global approach? Lancet Diabetes Endocrinol. 2018 May;6(5):356-358. doi: 10.1016/S2213-8587(17)30263-2. Epub 2017 Aug 7.</citation>
    <PMID>28797748</PMID>
  </reference>
  <reference>
    <citation>Woodcock J, LaVange LM. Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both. N Engl J Med. 2017 Jul 6;377(1):62-70. doi: 10.1056/NEJMra1510062.</citation>
    <PMID>28679092</PMID>
  </reference>
  <reference>
    <citation>Berry SM, Connor JT, Lewis RJ. The platform trial: an efficient strategy for evaluating multiple treatments. JAMA. 2015 Apr 28;313(16):1619-20. doi: 10.1001/jama.2015.2316.</citation>
    <PMID>25799162</PMID>
  </reference>
  <reference>
    <citation>Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, Ritchie AWS, Attard G, Chowdhury S, Cross W, Dearnaley DP, Gillessen S, Gilson C, Jones RJ, Langley RE, Malik ZI, Mason MD, Matheson D, Millman R, Russell JM, Thalmann GN, Amos CL, Alonzi R, Bahl A, Birtle A, Din O, Douis H, Eswar C, Gale J, Gannon MR, Jonnada S, Khaksar S, Lester JF, O'Sullivan JM, Parikh OA, Pedley ID, Pudney DM, Sheehan DJ, Srihari NN, Tran ATH, Parmar MKB, Sydes MR; Systemic Therapy for Advanced or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) investigators. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet. 2018 Dec 1;392(10162):2353-2366. doi: 10.1016/S0140-6736(18)32486-3. Epub 2018 Oct 21.</citation>
    <PMID>30355464</PMID>
  </reference>
  <reference>
    <citation>Park JW, Liu MC, Yee D, Yau C, van 't Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, DeMichele A, Buxton MB, Chien AJ, Wallace AM, Boughey JC, Haddad TC, Chui SY, Kemmer KA, Kaplan HG, Isaacs C, Nanda R, Tripathy D, Albain KS, Edmiston KK, Elias AD, Northfelt DW, Pusztai L, Moulder SL, Lang JE, Viscusi RK, Euhus DM, Haley BB, Khan QJ, Wood WC, Melisko M, Schwab R, Helsten T, Lyandres J, Davis SE, Hirst GL, Sanil A, Esserman LJ, Berry DA; I-SPY 2 Investigators. Adaptive Randomization of Neratinib in Early Breast Cancer. N Engl J Med. 2016 Jul 7;375(1):11-22. doi: 10.1056/NEJMoa1513750.</citation>
    <PMID>27406346</PMID>
  </reference>
  <reference>
    <citation>Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR Jr, Tsao A, Stewart DJ, Hicks ME, Erasmus J Jr, Gupta S, Alden CM, Liu S, Tang X, Khuri FR, Tran HT, Johnson BE, Heymach JV, Mao L, Fossella F, Kies MS, Papadimitrakopoulou V, Davis SE, Lippman SM, Hong WK. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov. 2011 Jun;1(1):44-53. doi: 10.1158/2159-8274.CD-10-0010. Epub 2011 Jun 1.</citation>
    <PMID>22586319</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 4, 2020</study_first_submitted>
  <study_first_submitted_qc>May 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2020</study_first_posted>
  <last_update_submitted>June 29, 2020</last_update_submitted>
  <last_update_submitted_qc>June 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Kidney Disease</keyword>
  <keyword>Diabetic Nephropathy</keyword>
  <keyword>Hypertensive Kidney Disease</keyword>
  <keyword>Glomerulonephritis</keyword>
  <keyword>Focal Segmental Glomerulosclerosis</keyword>
  <keyword>Membranous Nephropathy</keyword>
  <keyword>Minimal Change Disease</keyword>
  <keyword>IgA Nephropathy</keyword>
  <keyword>Glomerulonephritis not otherwise specified</keyword>
  <keyword>GN</keyword>
  <keyword>FSGS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The current plan is that only aggregate data will be shared for research purposes. IPD would only be reviewed in incidental findings and only be discussed with the participant in question.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

